|
Alzheimer's Combo Treatment OKd by FDA
Newsmax Health The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis and Adamas Pharmaceuticals. Adamas shares were up nearly 17 percent at $17.10 in premarket trading. The drug, Namzaric is … |
Day: December 24, 2014
UPDATE 1-Actavis, Adamas win FDA approval for Alzheimer’s drug – Reuters
Pharmaceutical Business Review |
UPDATE 1-Actavis, Adamas win FDA approval for Alzheimer's drug
Reuters (Adds details, background, share). Dec 24 (Reuters) – The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. Adamas shares were up nearly 17 … Actavis, Adamas Pharma Win FDA Approval For Alzheimer's Drug Namzaric Actavis Alzheimers Drug Approved; Bystolic Gets CRL Actavis, Adamas win FDA approval for Alzheimer's drug |
Actavis, Adamas win FDA approval for Alzheimer’s drug – Reuters
Pharmaceutical Business Review |
Actavis, Adamas win FDA approval for Alzheimer's drug
Reuters (Reuters) – The U.S. Food and Drug Administration approved a drug to treat dementia in Alzheimer's patients that was developed by Actavis Plc and Adamas Pharmaceuticals Inc. Adamas shares were up nearly 17 percent at $17.10 in premarket trading. Actavis, Adamas Pharma Win FDA Approval For Alzheimer's Drug Namzaric |